TABLE 2.
Univariate logistic analysis of factors influencing the efficacy of neoadjuvant chemotherapy.
| Factors | TRG | RECIST1.1 | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | p | OR | 95% CI | p | |
| Age | 0.998 | 0.966–1.030 | 0.885 | 1.005 | 0.973–1.037 | 0.781 |
| Sex | ||||||
| Female | Reference | Reference | ||||
| Male | 0.409 | 0.156–0.957 | 0.051 | 0.647 | 0.277–1.425 | 0.293 |
| Tumor location | ||||||
| Diffuse type | Reference | Reference | ||||
| Lower | 0.759 | 0.217–2.389 | 0.647 | 1.012 | 0.308–3.137 | 0.983 |
| Middle | 0.712 | 0.202–2.254 | 0.573 | 0.782 | 0.237–2.430 | 0.673 |
| Upper | 1.143 | 0.309–3.874 | 0.833 | 1.524 | 0.438–5.086 | 0.495 |
| Differentiation (before NACT) | ||||||
| Poorly | Reference | Reference | ||||
| Moderate and well | 4.800 | 2.208–11.666 | 0.001 | 5.387 | 2.480–13.091 | 0.001 |
| cT stage | ||||||
| 2 | Reference | Reference | ||||
| 3 | 0.488 | 0.134–1.422 | 0.223 | 0.507 | 0.139–1.477 | 0.248 |
| 4 | 0.168 | 0.043–0.533 | 0.005 | 0.107 | 0.027–0.345 | <0.001 |
| cN stage | ||||||
| Negative | Reference | Reference | ||||
| Positive | 1.175 | 0.576–2.354 | 0.652 | 0.811 | 0.391–1.632 | 0.562 |
| cTNM | ||||||
| III | Reference | Reference | ||||
| IIa | 1.799 | 0.872–3.810 | 0.117 | 3.077 | 1.460–6.784 | 0.004 |
| IIb | 1.407 | 0.707–2.837 | 0.333 | 1.565 | 0.794–3.122 | 0.198 |
| BMI | ||||||
| 18.5–24 | Reference | Reference | ||||
| <18.5 or >24 | 1.413 | 0.764–2.660 | 0.276 | 0.992 | 0.543–1.826 | 0.979 |
| Tumor diameter | ||||||
| <5 cm | Reference | Reference | ||||
| ≥5 cm | 0.329 | 0.178–0.602 | <0.001 | 0.354 | 0.192–0.643 | 0.001 |
| Chemotherapy cycles | ||||||
| 2–3 | Reference | Reference | ||||
| 4 | 1.798 | 0.977–3.374 | 0.063 | 1.281 | 0.707–2.344 | 0.417 |
| ASA | ||||||
| 1 and 2 | Reference | Reference | ||||
| 3 | 1.534 | 0.722–3.445 | 0.279 | 1.465 | 0.698–3.220 | 0.324 |